Drug Profile
Hepatitis E vaccine recombinant - Changchun Institute of Biological Products
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Changchun Institute of Biological Products
- Developer Changchun Institute of Biological Products; Jiangsu Provincial Center for Disease Control and Prevention
- Class Synthetic vaccines; Viral hepatitis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis E
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Hepatitis-E(Prevention) in China (Parenteral)
- 20 Sep 2016 Jiangsu Province Centers for Disease Control and Prevention in collaboration with Changchun Institute of Biological Products complete a phase I clinical trial in Hepatitis E (Prevention) in China (Parenteral) (NCT02603055)
- 01 Jul 2015 Phase-I clinical trials in Hepatitis E (Prevention) in China (Parenteral)